Boston Scientific acquires Penumbra for $14.5 billion

• Deal value: $14.5 billion total, pricing Penumbra at $374 per share
• Strategic rationale: Acquisition aimed at expanding Boston Scientific's vascular product pipeline
• Transaction expected to be completed in 2026

Boston Scientific Acquires Penumbra for $14.5 Billion

Key Transaction Details:

Boston Scientific announced Thursday it will acquire Penumbra in an all-cash deal valued at approximately $14.5 billion. The transaction values Penumbra at $374 per share and is expected to close in 2026.

Strategic Rationale:

The acquisition aims to expand Boston Scientific's vascular pipeline, strengthening its position in the medical device sector. Both companies operate in the healthcare technology space, with focus on vascular and surgical solutions.

Companies Involved:

• Boston Scientific: A major medical device manufacturer and developer, acquiring company
• Penumbra: Target company specializing in vascular medical devices

Market Implications:

This represents one of the significant healthcare M&A transactions, reflecting continued consolidation in the medical device industry. The deal demonstrates Boston Scientific's aggressive growth strategy and commitment to enhancing its vascular product portfolio. The premium valuation at $374 per share suggests strong strategic value in Penumbra's technology and market position.

The 2026 completion timeline indicates the transaction will require standard regulatory approvals and customary closing conditions. This acquisition positions Boston Scientific to capture greater market share in the vascular intervention space, potentially affecting competitive dynamics among medical device manufacturers.

The deal underscores ongoing trends in healthcare: established players acquiring innovative technology companies to expand capabilities and market reach in specialized therapeutic areas.